Synlait Buys Pokeno Plant – $307m Deal, Net Loss Reduced

Area	details
sale Impact	Provides “freedom to move forward” and focus on earning the right to grow over the next six months.
Manufacturing issues	Multiple “micro” issues across engineering,plants,people,and processes – not a single major problem. These were “one-offs”.
cost Implications	Issues in advanced nutrition production quickly increase costs and require support for customers.
a2 Milk Relationship	Trade with a2 Milk (Synlait’s biggest customer) was not hindered by the issues. Synlait is currently a2 Milk’s sole infant formula supplier.
a2 Milk’s Future Manufacturing	a2 Milk is becoming its own manufacturer with the purchase of Yashili’s plant in Pōkeno for $282m.
SAMR Registration	Synlait has registration from china’s SAMR to produce China label formula for a2 Milk,renewable in 2027.
Production Shift	a2 Milk’s new plant will likely handle Synlait’s English label product, but Synlait may still have opportunities to produce it.
Debt Status	Synlait is on track to be debt-free by the end of 2026.
Future Investment	The board is expected to be cautious about future investments. CEO would advocate for a debt equity ratio of 20-25%.
Sharemarket Reaction	Synlait shares increased 11.5c to 81.5c following the sale proclamation.
Sale Significance	The sale to Abbott (an existing major customer) is considered a “defining moment” for Synlait.